Lung Cancer

Screening for Lung Cancer
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer.
Read Article

Smoking Cessation and Lung Cancer
Dr. Edward Garon discusses the importance of smoking cessation programs for patients diagnosed with lung cancer.
Read Article

The rising cost of healthcare, including cancer care, is an established trend in the United States. In 2015, Americans spent $3.2 trillion (nearly $10,000 per person) on healthcare, including hospital inpatient and outpatient care, physicians’ services, and prescription drugs. The National Cancer Institute estimates that by 2020, the annual cost of healthcare for Americans with cancer will reach $156 billion; based on current trends, this means that cancer care will represent approximately 20% of the country’s annual healthcare expenditures.
Read Article

Common Concerns in Managing Patients with NSCLC
Dr Edward Garon provides an overview of the main concerns he has in managing patients with NSCLC, citing pseudoprogression as one of the biggest misconceptions.
Read Article

Improving Lung Cancer Screening
Dr Suresh Ramalingam discusses the importance of screening for lung cancer and identifies the ideal patients to target for screening.
Read Article

Individualizing Treatment for Lung Cancer
Dr Suresh Ramalingam examines the factors he considers when making treatment decisions for his patients.
Read Article

What's Ahead for Treating NSCLC
Although Dr Edward Garon feels the future of NSCLC is unclear, he cites how treatment has progressed over the years and wonders how immunotherapies and combination therapies will impact treatment.
Read Article

Copenhagen, Denmark—Immunotherapy for advanced non–small-cell lung cancer (NSCLC) took a step toward first-line indication as results from a randomized clinical trial showed that patients who received pembrolizumab (Keytruda) plus chemotherapy had a significantly higher response rate compared with patients who received chemotherapy alone, reported Corey J. Langer, MD, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, at the 2016 European Society for Medical Oncology (ESMO) Congress. The clinical trial results (KEYNOTE-021) were also published in Lancet Oncology, and are available online.
Read Article

Copenhagen, Denmark—Immunotherapy competition in non–small-cell lung cancer (NSCLC) continued to heat up as atezolizumab (Tecentriq) improved overall survival (OS) versus docetaxel, according to results from the randomized, phase 3 OAK clinical trial reported at the 2016 European Society for Medical Oncology Congress by Fabrice Barlesi, MD, Professor of Medicine, Aix-Marseille University, France.
Read Article

Copenhagen, Denmark—Patients with heavily pretreated ALK mutation and non–small-cell lung cancer (NSCLC) had significant improvement in progression-free survival (PFS) after receiving the next-generation ALK inhibitor ce­ritinib, according to results from the ASCEND-5 study reported at the 2016 European Society for Medical Oncology Congress by Giorgio Scagliotti, MD, Professor of Respiratory Medicine, University of Torino, Italy.
Read Article

Page 7 of 9